Stellar Biotechnologies, Inc. has submitted a provisional application for a patent to the US Patent and Trademark Office for new innovations related to Stellar's Keyhole Limpet Hemocyanin-based combinatorial adjuvant technology.
The application included claims for pharmaceutical grade adjuvant compositions, manufacturing processes and uses in a wide range of vaccine therapies. Stellar's Keyhole Limpet Hemocyanin (KLH)-based adjuvant platform has the potential to improve vaccine potency, reduce toxicities and offer highly targeted immune activation.
"One of the biggest challenges in developing therapeutic vaccines has been the need for safe, robust adjuvants," said Stellar CTO, Herbert Chow. "Stellar Biotechnologies has developed a new combinatorial adjuvant technology based on the long-standing safety and well-recognized immune-stimulating properties of KLH."
Stellar President and CEO Frank Oakes said, "Vaccine adjuvants have multi-billion market potential. We believe Stellar's KLH-based approach, and new intellectual property, positions us to enter this industry field, and will be valuable to major pharmaceutical partners."